抗淀粉样蛋白免疫治疗III期试验中ARIA发生率:更新荟萃分析
该荟萃分析纳入8项III期随机对照试验共6315例轻中度阿尔茨海默病患者,评估抗Aβ免疫治疗中ARIA发生率。ARIA-E合并发生率为9.5%,敏感性分析校正后为25.5%;ARIA-H合并发生率为17.8%。APOE ε4纯合子携带者发生ARIA-E的比值比为5.6(95% CI 3.8-8.2,p<0.001)。
要点
- ARIA-E合并发生率9.5%,敏感性分析校正后为25.5%。
- ARIA-H合并发生率17.8%,孤立性ARIA-H为8.7%。
- APOE ε4纯合子发生ARIA-E的OR为5.6(95% CI 3.8-8.2)。
核心结论
- 在抗Aβ免疫治疗III期随机对照试验中,ARIA-E校正合并发生率为25.5%,ARIA-H合并发生率为17.8%。
- APOE ε4纯合子携带者发生ARIA-E的风险为非携带者的5.6倍。
研究设计与样本
- 检索PubMed和Embase数据库截至2024年5月23日发表的抗Aβ免疫治疗III期随机对照试验。
- 纳入因阿尔茨海默病所致轻度认知障碍或轻度阿尔茨海默病痴呆、且ARIA-E/H数据充分的III期试验。
- 共纳入8项研究的9个III期随机对照试验队列,分析6315例患者数据。
- 计算ARIA合并发生率,并按不同药物和APOE ε4携带状态进行亚组分析,另进行排除离群值的敏感性分析。
主要发现
- ARIA-E合并发生率为9.5%(95% CI 2.8%-27.3%),敏感性分析校正后合并发生率为25.5%(95% CI 20.4%-31.8%)。
- 症状性ARIA-E合并发生率为6.7%(95% CI 3.5%-12.5%),严重ARIA-E合并发生率为3.5%(95% CI 13.8%-8.4%)。
- ARIA-H合并发生率为17.8%(95% CI 11.0%-27.5%),表面铁沉积发生率为9.3%(95% CI 6.1%-13.9%),孤立性ARIA-H合并发生率为8.7%(95% CI 7.6%-10.1%)。
- APOE ε4纯合子携带者发生ARIA-E的比值比(OR)为5.6(95% CI 3.8-8.2,p<0.001),高于非携带者。
- APOE ε4杂合子携带者发生ARIA-E的OR为1.9(95% CI 1.5-2.4,p<0.001),高于非携带者。
临床怎么用
- 在抗Aβ免疫治疗III期试验中,ARIA-E校正合并发生率为25.5%,ARIA-H合并发生率为17.8%。
- APOE ε4纯合子携带者发生ARIA-E的OR为5.6(95% CI 3.8-8.2,p<0.001),杂合子OR为1.9(95% CI 1.5-2.4,p<0.001)。
局限性
- 原文述局限性包括样本量小和队列水平数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Amyloid-related imaging abnormalities (ARIA) are key safety considerations in anti-amyloid-β (Aβ) immunotherapy. ARIA can be categorized into 2 types: ARIA characterized by edema and effusion (ARIA-E) or microhemorrhages and superficial siderosis (ARIA-H). In this study, we assessed the incidence of ARIA in phase 3 randomized controlled trials (RCTs) of anti-Aβ immunotherapy and compared the incidence among different agents and APOE ε4 carrier status. METHODS: PubMed and Embase databases were searched for phase 3 RCTs of anti-Aβ immunotherapy published on or before May 23, 2024. The inclusion criteria were phase 3 trials of anti-Aβ immunotherapy for mild cognitive impairment due to Alzheimer disease (AD) or mild AD dementia, with sufficient data on ARIA-E/H. The pooled incidences of ARIA and subgroup analyses according to various agents and APOE ε4 carrier status were calculated. A sensitivity analysis excluding outliers was performed. The pooled odds ratio (OR) of ARIA-E according to the APOE ε4 carrier status was also calculated. RESULTS: Nine phase 3 RCT cohorts from 8 eligible studies were identified, analyzing data from 6,315 patients. The pooled incidence of ARIA-E was 9.5% (95% CI 2.8%-27.3%), and the adjusted pooled incidence of ARIA-E was 25.5% (95% CI 20.4%-31.8%) in the sensitivity analysis. The pooled incidence of symptomatic ARIA-E was 6.7% (95% CI 3.5%-12.5%) and that of severe ARIA-E was 3.5% (95% CI 13.8%-8.4%). The pooled incidence of ARIA-H was 17.8% (95% CI 11.0%-27.5%), with the incidence of superficial siderosis was 9.3% (95% CI 6.1%-13.9%). The pooled incidence of isolated ARIA-H was 8.7% (95% CI 7.6%-10.1%). Subgroup analysis showed that homozygous APOE ε4 carriers had significantly higher odds of developing ARIA-E (OR 5.6, 95% CI 3.8-8.2, p < 0.001) than noncarriers. Heterozygous APOE ε4 carriers also had significantly higher odds of developing ARIA-E (OR 1.9, 95% CI 1.5-2.4, p < 0.001) than noncarriers. DISCUSSION: Although limited by small sample size and cohort-level data, our meta-analysis shows the adjusted pooled incidence of ARIA-E was 25.5% and the pooled incidence of ARIA-H was 17.8% in the recent phase 3 RCTs of anti-Aβ immunotherapy. Homozygous APOE ε4 carriers have a 5.6-fold higher risk of developing ARIA-E than noncarriers.
引用
- Jeong SY, Suh CH, Lim JS, et al. Incidence of Amyloid-Related Imaging Abnormalities in Phase III Clinical Trials of Anti-Amyloid-β Immunotherapy: An Updated Meta-Analysis. Neurology. 2025. PMID: 40112274. doi:10.1212/WNL.0000000000213483
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。